Notizia

Celgene has finally confirmed the week-long rumor of buying Juno Therapeutics for a deal worth around USD 9 billion boosting its Grip in CAR-T therapy domain. A major reason for this buyout is Juno’s lead CAR-T drug candidate JCAR017 that is expected to get the FDA approval next year with an estimated market potential of around USD 3 billion.

Eureka bags a funding of USD 60 million to take T-cell therapy into the clinical trials

Eureka Therapeutics is heading forward with full swing after getting USD 60 million in series D round. The funding will facilitate the phase I development of companies’ lead T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma. Funds raising was backed by Acorn Pacific Ventures and GP Capital, helping the company to expand horizons in solid tumors as well as other blood cancers.

After failed deals, Ablynx investor has now opened door to Novo deal at a higher price

After multiple failed attempts Ablynx’s largest shareholder has now opened door to Novo Nordisk deal but in return for a higher offering price. After rejecting the USD 3.2 billion takeover offering multiple times Ablynx’s largest shareholder is now expecting Novo or a rival to return with a much higher bid price.

Torrent Pharma has indicated that in the upcoming meeting scheduled on January 25 the board will consider fundraising. It could be either in form of issuance of equity shares (including convertible/non-convertible debentures/bonds) through QIP or by way of private placement or any other way.